A Phase 3 interventional study of Vancomycin inhalation powder and Placebo inhalation powder in MRSA and Cystic Fibrosis, sponsored by Savara Inc.. Completed at 71 sites in 2 countries. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2022-12-16.
Sponsored by Savara Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 717 studies in Cystic Fibrosis with a site in United States — 86 open to participants now, 111 under way, 8 of them phase 3. Cystic Fibrosis · United States.
Among the 717 studies in Cystic Fibrosis with a site in United States, this one is the 67th largest by enrollment of the 517 interventional ones that give a count, is one of 34 that started in 2017, is one of 100 in phase 3, and was the 431st registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →86 of the 717 studies in Cystic Fibrosis with a site in United States are open now. Recruiting first, the newest first:
Bettina Mittendorfer · Sites in United States
Ages 18–100 · Healthy volunteers
Aimmune Nestlé Health Science US R&D, LLC · Sites in United States, Bulgaria, Hungary and 4 more countries
Ages 18–85
Dartmouth-Hitchcock Medical Center · Sites in United States
Ages 3–18
Ghady Haidar · Sites in United States
Ages 18+
Anagram Therapeutics, Inc. · Sites in United States
Ages 12+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 6 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
717 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 109 · Phase 2 143 · Phase 3 108 · Phase 4 47
First in 1988; this study’s year is marked. 34 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 188 is above the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 36 across the 517 interventional studies, 80 across the 193 observational. Of the 569 that completed or were terminated, 263 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
250 of 717 have an industry lead sponsor. The 10 most frequent:
Savara Inc. is the lead sponsor of 11 studies on the registry; 2 are open to participants now.
Savara Inc. has 5 studies filed under Cystic Fibrosis — fewer than ten, so there is no comparison to draw.
43 of the studies in Cystic Fibrosis with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06413368Phase 3Children's Hospital Los AngelesMaralixibat in Patients With Cystic Fibrosis and Constipation | 2027-06-30 |
| NCT06449677Phase 3Jaeb Center for Health ResearchBionic Pancreas in CFRD | 2027-06-30 |
| NCT06996951Phase 3Indiana UniversitySinonasal Therapies and Histologic Correlations of Patients With Cystic Fibrosis in the Era of Highly Effective Modulator Therapy | 2027-07 |
| NCT06237335ReCode TherapeuticsA Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF | 2026-11 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
Add all 43 to your calendar (.ics) → With an account.
Among the 717 studies in Cystic Fibrosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multi-center, randomized phase III study to evaluate the clinical effectiveness of AeroVanc in persistent methicillin-resistant Staphylococcus aureus (MRSA) infection in patients with cystic fibrosis (CF).
This is a phase III, randomized, multicenter, double-blind, placebo-controlled, parallel-group study to examine the safety and efficacy of AeroVanc in the treatment of persistent MRSA lung infection in patients diagnosed with CF. After the Screening period to confirm study eligibility, participants are randomly assigned in a blinded fashion to receive either AeroVanc 30 mg twice daily (BID), or placebo BID (1:1 active to placebo) by inhalation for 24 weeks or 3 dosing cycles (Period 1). Upon completion of Period 1, participants receive open-label AeroVanc 30 mg BID for an additional 24 weeks or 3 dosing cycles (Period 2), to evaluate long-term safety of AeroVanc. A dosing cycle is defined as 28 days of treatment followed by 28 days of observation.
Participants on a 28-day cyclical on/off anti-Pseudomonal antibiotic regimen enter the Screening period at a time such that the Baseline visit coincide with the end of their anti-Pseudomonas antibiotic cycle. Study drug is thereby administered during the off-cycle, and participants can then resume anti-Pseudomonal therapy during the 28-day observation period. Participants continuing alternating anti-Pseudomonal therapy can continue their treatment during the study drug administration, and observation period.
The primary and secondary analyses are conducted in participants ≤21 years old. Subjects >21 years old are analyzed separately as supportive analyses.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Confirmed diagnosis of CF, determined by having clinical features consistent with the CF phenotype, plus one of the following:
If female of , an acceptable method of must be used during the study and must be combined with a negative pregnancy test obtained during Screening; sexually active male subjects of who are non-sterile (i.e., male who has not been sterilized by vasectomy for at least 6 months, and were not diagnosed with infertility through demonstration of azoospermia in a semen sample and/or absence of vas deferens through ultrasound) must be willing to use a barrier method of contraception, or their female partner must use an acceptable method of contraception, during the study.
For purposes of this study, the Sponsor defines "acceptable methods of contraception" as:
Note: For subjects prescribed Orkambi: Orkambi may substantially decrease hormonal contraceptive exposure, reducing the effectiveness and increasing the incidence of menstruation-associated adverse reactions. Hormonal contraceptives, including oral, injectable, transdermal, and implantable, should not be relied upon as an effective method of contraception when co-administered with Orkambi.
Exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vancomycin inhalation powder 30 mg is administered twice daily (BID) during the 24-week double-blind period (Period 1) by inhalation during three dosing cycles, each cycle being 28 days of treatment followed by 28 days of observation.
Drug: Vancomycin inhalation powder
Matching placebo is administered BID during the 24-week double-blind period (Period 1) by inhalation during three dosing cycles, each cycle being 28 days of treatment followed by 28 days of observation.
Drug: Placebo inhalation powder
In the 24-week Period 2, all participants receive AeroVanc 30 mg BID by inhalation during three dosing cycles, each cycle being 28 days of treatment followed by 28 days of observation.
Drug: Vancomycin inhalation powder
100 participants are to be treated with double-blind vancomycin inhalation powder (75 subjects ≤21 years old, 25 subjects \>21 years old) for 24 weeks during Period 1.
Also known as: AeroVanc
100 participants are to be treated with double-blind placebo (75 subjects ≤21 years old, 25 subjects \>21 years old) for 24 weeks during Period 1.
In the 24-week Period 2, all participants are to be treated with open-label vancomycin inhalation powder.
Also known as: AeroVanc
Absolute Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Percent Predicted
The mean absolute change from baseline in FEV1 percent predicted was analyzed sequentially at Week 4 (end of Cycle 1), Week 12 (end of Cycle 2) and at Week 20 (end of Cycle 3).
Time frame: Baseline and Week 4, 12 and 20
Frequency of Pulmonary Exacerbations
The number of pulmonary exacerbations during Period 1 adjusted for the length of follow-up.
Time frame: Week 20
Time to First Pulmonary Exacerbation
Time to first pulmonary exacerbation requiring use of another antibiotic medication (oral, IV, and/or inhaled). The Outcome Measure Data presented are the median percentiles and 95% confidence intervals from Kaplan-Meier estimates.
Time frame: Week 20
Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Scores
The CFQ-R was administered every two weeks using a hand-held e-Diary. CFQ-R scores range between 0 and 100, where higher scores indicate a better outcome. The CFQ-R measures functioning in a variety of domains, including Physical Functioning, Vitality, Health Perceptions, Respiratory Symptoms, Treatment Burden, Role Functioning, Emotional Functioning and Social Functioning. The Outcome Measure Data presented are the Respiratory Symptoms Scores.
Time frame: Baseline and Week 4, 12, and 20
Change From Baseline in Cystic Fibrosis Respiratory Symptom Diary-Chronic Respiratory Symptom Score (CFRSD-CRISS) Scores
The CFRSD-CRISS was administered every two weeks using a hand-held e-Diary. Scores range between 0 and 100, where higher scores indicate a worse outcome.
Time frame: Baseline and Week 4, 12 and 20
Relative Change in FEV1 Percent Predicted
The mean relative change from Baseline in FEV1 percent predicted
Time frame: Baseline and Week 4, 12 and 20
Number of Successful Response Cycles
The number of successful response cycles a participant achieves over Period 1. A response in a cycle is defined by at least a 5 % relative improvement in FEV1 percent predicted at the end of each the respective cycle.
Time frame: Week 20
Area Under the FEV1-time Profile
The mean treatment difference in FEV1 across all post-baseline visits
Time frame: Week 20
76 sites in Canada (2 clinics) and US (74 clinics) enrolled participants in the trial. First participant was enrolled on 20 September 2017 and last subject completed the study on 15 January 2021.
| Milestone | Double-blind Vancomycin Inhalation Powder | Double-blind Placebo Inhalation Powder |
|---|---|---|
| Started | 90 | 98 |
| Completed | 79 | 85 |
| Not completed | 11 | 13 |
| Withdrew: Adverse event | 5 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Protocol violation | 1 | 2 |
| Withdrew: Withdrawal by subject | 5 | 9 |
| Milestone | Double-blind Vancomycin Inhalation Powder | Double-blind Placebo Inhalation Powder |
|---|---|---|
| Started | 75 | 83 |
| Completed | 67 | 70 |
| Not completed | 8 | 13 |
| Withdrew: Adverse event | 1 | 6 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Protocol violation | 3 | 1 |
| Withdrew: Withdrawal by subject | 2 | 5 |
| Withdrew: Reason missing | 2 | 0 |
The mean absolute change from baseline in FEV1 percent predicted was analyzed sequentially at Week 4 (end of Cycle 1), Week 12 (end of Cycle 2) and at Week 20 (end of Cycle 3).
| Percent predicted | Double-blind Vancomycin Inhalation Powder | Double-blind Placebo Inhalation Powder |
|---|---|---|
| Week 4 | 2.39 ± 8.078 | 1.18 ± 8.581 |
| Week 12 | 1.52 ± 8.414 | 0.13 ± 8.056 |
| Week 20 | 1.61 ± 9.967 | -1.94 ± 8.924 |
The number of pulmonary exacerbations during Period 1 adjusted for the length of follow-up.
| exacerbations | Double-blind Vancomycin Inhalation Powder | Double-blind Placebo Inhalation Powder |
|---|---|---|
| Frequency of Pulmonary Exacerbations | 0.9 ± 1.03 | 0.9 ± 1.02 |
Time to first pulmonary exacerbation requiring use of another antibiotic medication (oral, IV, and/or inhaled). The Outcome Measure Data presented are the median percentiles and 95% confidence intervals from Kaplan-Meier estimates.
| days | Double-blind Vancomycin Inhalation Powder | Double-blind Placebo Inhalation Powder |
|---|---|---|
| Time to First Pulmonary Exacerbation | 38 (18 to 49) | 48 (29 to 59) |
The CFQ-R was administered every two weeks using a hand-held e-Diary. CFQ-R scores range between 0 and 100, where higher scores indicate a better outcome. The CFQ-R measures functioning in a variety of domains, including Physical Functioning, Vitality, Health Perceptions, Respiratory Symptoms, Treatment Burden, Role Functioning, Emotional Functioning and Social Functioning. The Outcome Measure Data presented are the Respiratory Symptoms Scores.
| score on a scale | Double-blind Vancomycin Inhalation Powder | Double-blind Placebo Inhalation Powder |
|---|---|---|
| Week 4 | 8.4 (4.2 to 12.7) | 3.0 (-1.0 to 7.0) |
| Week 12 | 6.0 (1.4 to 10.6) | 4.3 (-0.2 to 8.9) |
| Week 20 | 4.6 (-0.8 to 10.1) | 6.3 (1.2 to 11.4) |
The CFRSD-CRISS was administered every two weeks using a hand-held e-Diary. Scores range between 0 and 100, where higher scores indicate a worse outcome.
| score on a scale | Double-blind Vancomycin Inhalation Powder | Double-blind Placebo Inhalation Powder |
|---|---|---|
| Week 4 | -3.2 (-7.3 to 0.9) | -5.1 (-9.1 to -1.1) |
| Week 12 | -4.7 (-10.1 to 0.6) | -8.0 (-13.3 to -2.8) |
| Week 20 | -7.3 (-12.5 to -2.0) | -5.3 (-10.3 to -0.4) |
The mean relative change from Baseline in FEV1 percent predicted
| percent predicted | Double-blind Vancomycin Inhalation Powder | Double-blind Placebo Inhalation Powder |
|---|---|---|
| Week 4 | 2.9 (-1.0 to 6.8) | 1.5 (-2.1 to 5.1) |
| Week 12 | 1.2 (-2.8 to 5.2) | -0.3 (-4.1 to 3.5) |
| Week 20 | 1.7 (-2.7 to 6.1) | -2.2 (-6.4 to 2.0) |
The number of successful response cycles a participant achieves over Period 1. A response in a cycle is defined by at least a 5 % relative improvement in FEV1 percent predicted at the end of each the respective cycle.
| Participants | Double-blind Vancomycin Inhalation Powder | Double-blind Placebo Inhalation Powder |
|---|---|---|
| 0 successful response cycles | 20 | 24 |
| 1 successful response cycle | 18 | 27 |
| 2 successful response cycles | 15 | 9 |
| 3 successful response cycles | 9 | 6 |
The mean treatment difference in FEV1 across all post-baseline visits
| percent predicted*hour/liter | Double-blind Vancomycin Inhalation Powder | Double-blind Placebo Inhalation Powder |
|---|---|---|
| Area Under the FEV1-time Profile | 609.7 (520.8 to 698.7) | 583.1 (499.8 to 666.5) |
Collected over Treatment-emergent adverse events (AEs) were assessed on or after the first dose of trial drug to 28 days after last dose. For all safety analyses, a single set of results was produced including all participants (6-21 and >21 years combined). For the double-blind Period 1, AE data are presented for the vancomycin and placebo groups whereas for the open-label Period 2, AE data for only one combined group is presented.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Double-blind Vancomycin Inhalation Powder | 0/90 (0%) | 24/90 (26.7%) | 85/90 (94.4%) |
| Double-blind Placebo Inhalation Powder | 0/98 (0%) | 35/98 (35.7%) | 93/98 (94.9%) |
| Open-label Vancomycin Inhalation Powder | 0/158 (0%) | 50/158 (31.6%) | 139/158 (88%) |
| Event | Double-blind Vancomycin Inhalation Powder | Double-blind Placebo Inhalation Powder | Open-label Vancomycin Inhalation Powder |
|---|---|---|---|
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 19/90 | 29/98 | 38/158 |
| ConstipationGastrointestinal disorders | 2/90 | 4/98 | 2/158 |
| PneumoniaInfections and infestations | 2/90 | 3/98 | 3/158 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 1/90 | 2/98 | 2/158 |
| BronchitisInfections and infestations | 0/90 | 0/98 | 3/158 |
| Pneumonia staphylococcalInfections and infestations | 1/90 | 1/98 | 0/158 |
| InfluenzaInfections and infestations | 1/90 | 0/98 | 0/158 |
| Staphylococcal infectionInfections and infestations | 1/90 | 0/98 | 0/158 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/90 | 0/98 | 0/158 |
| Cystic fibrosis related diabetesCongenital, familial and genetic disorders | 1/90 | 0/98 | 0/158 |
| Event | Double-blind Vancomycin Inhalation Powder | Double-blind Placebo Inhalation Powder | Open-label Vancomycin Inhalation Powder |
|---|---|---|---|
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 51/90 | 59/98 | 78/158 |
| CoughRespiratory, thoracic and mediastinal disorders | 42/90 | 36/98 | 40/158 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 8/90 | 12/98 | 9/158 |
| HeadacheNervous system disorders | 9/90 | 12/98 | 12/158 |
| PyrexiaGeneral disorders | 11/90 | 8/98 | 8/158 |
| VomitingGastrointestinal disorders | 9/90 | 11/98 | 0/158 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 7/90 | 10/98 | 8/158 |
| NauseaGastrointestinal disorders | 4/90 | 10/98 | 8/158 |
| Chest discomfortGeneral disorders | 9/90 | 8/98 | 0/158 |
| WheezingRespiratory, thoracic and mediastinal disorders | 3/90 | 8/98 | 7/158 |
The number of baseline participants include both age groups (participants 6-21 years and \>21 years).
| Age, Continuous(years) | Double-blind Vancomycin Inhalation Powder | Double-blind Placebo Inhalation Powder | Total |
|---|---|---|---|
| Mean | 20.2 ± 12.52 | 18.2 ± 8.70 | 19.2 ± 10.71 |
| Age, Customized(Participants) | Double-blind Vancomycin Inhalation Powder | Double-blind Placebo Inhalation Powder | Total |
|---|---|---|---|
| 6-21 years | 64 | 69 | 133 |
| >21 years | 26 | 29 | 55 |
| Sex: Female, Male(Participants) | Double-blind Vancomycin Inhalation Powder | Double-blind Placebo Inhalation Powder | Total |
|---|---|---|---|
| Female | 45 | 50 | 95 |
| Male | 45 | 48 | 93 |
| Ethnicity (NIH/OMB)(Participants) | Double-blind Vancomycin Inhalation Powder | Double-blind Placebo Inhalation Powder | Total |
|---|---|---|---|
| Hispanic or Latino | 4 | 6 | 10 |
| Not Hispanic or Latino | 86 | 92 | 178 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Double-blind Vancomycin Inhalation Powder | Double-blind Placebo Inhalation Powder | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 3 | 1 | 4 |
| White | 85 | 94 | 179 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 2 | 4 |
| Pseudomonas Aeruginosa Infection Present at Screening (Yes/No?)(Participants) | Double-blind Vancomycin Inhalation Powder | Double-blind Placebo Inhalation Powder | Total |
|---|---|---|---|
| Yes | 51 | 45 | 96 |
| No | 39 | 53 | 92 |
| Number of Pulmonary Infections in the Previous Year(infections) | Double-blind Vancomycin Inhalation Powder | Double-blind Placebo Inhalation Powder | Total |
|---|---|---|---|
| Mean | 2.6 ± 1.53 | 2.6 ± 1.44 | 2.6 ± 1.48 |
| Baseline Forced Expiratory Volume in 1 Second (FEV1) Percent Predicted(percent predicted) | Double-blind Vancomycin Inhalation Powder | Double-blind Placebo Inhalation Powder | Total |
|---|---|---|---|
| Mean | 65.25 ± 16.193 | 66.32 ± 16.939 | 65.81 ± 16.550 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2017 to primary completion in Jul 2020, 34 months.
Results were first posted in Nov 2021, 1 year 3 months after primary completion.
Of 58 industry-sponsored phase 3 interventional studies under Cystic Fibrosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 34 months is above that.
Counting every sponsor, half of 67 studies reached it within 26 months; a quarter within 16 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Savara Inc.